The latest research from Fore Pharma, ‘Europe Anti-Parkinsons Market Highlights – 2015’, provides the Europe Anti-Parkinsons market valuation, competitive landscape, and Anti-Parkinsons products sales in Europe. The research includes Europe Anti-Parkinsons market size estimates for 2014, Anti-Parkinsons products market share, and Anti-Parkinsons products sales estimates. This research helps executives track competitor product sales and market share in the Europe Anti-Parkinsons market. It supports decision making in R&D to long term marketing strategies. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Europe Anti-Parkinsons market.
Scope of the Research:
Anti-Parkinsons as defined in EphMRA Anatomical Therapeutic Chemical classification code N4A
Marketed Products: Identify Anti-Parkinsons products marketed including brand name, molecule name, and company
Sales Estimates: Find out estimates for the Europe Anti-Parkinsons market size in 2014, key products and their sales, and how the market and products advanced from 2011. You will benefit from our accurate sales valuation of products and the market
Geographic Landscape: Find out the Anti-Parkinsons market size in top 5 pharmaceutical markets in Europe - Germany, France, Italy, Spain, and UK
Competitive Landscape: You will know the market share of leading Anti-Parkinsons products in 2014 and how they have changed from 2011
Pipeline: Find out key Anti-Parkinsons products in clinical trial phase 3 and phase 2. Coverage includes molecule, mechanism of action, and the company developing the product